SCOT Scleroderma Treatment Alternative Registry (STAR Registry)
The Scleroderma Cyclophosphamide Or Transplant (SCOT) Trial is a Phase II/III interventional trial comparing two treatments for early, severe scleroderma. These two interventions are high dose immunosuppressive therapy followed by autologous stem cell transplantation and monthly high dose pulse cyclophosphamide (the later for 12 doses). While standard of care might be considered the optimal control arm for a trial such as this one, no such standard of care is available for the population of scleroderma patients defined by the eligibility criteria for this trial. The rheumatologists on the protocol team believe that the SCOT cyclophosphamide regimen represents the best control arm for this study. However, given concerns over use of a treatment arm as a control that has not been established as a standard of care, this registry was established. The registry will be a prospective, observational study of subjects with severe systemic sclerosis (SSc) who are eligible to participate in the Scleroderma Cyclophosphamide or Transplantation (SCOT) Study but are denied insurance coverage or decline to participate prior to randomization. Subjects will be accrued over the same period as the SCOT study. Subjects will follow the course of treatment prescribed by their treating physician with no interference from the registry.
The primary purpose of this study is to document the disease course and outcome in a group of participants who are eligible for the SCOT study, but declined to participate, in order to determine whether their outcome is better, worse, or no different than those who participate in the treatment phase of the trial.
Drug: currently available therapy in the community
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||An Observational, Long-term Follow-up Study of Eligible Individuals Declining To Participate in the Scleroderma Cyclophosphamide or Transplantation (SCOT) Study (SCSSc-02)|
- Event-free survival (EFS) [ Time Frame: 44 months after subject enrollment ] [ Designated as safety issue: No ]
The events will be defined as any one of the following:
- Respiratory failure defined as the need for supplementary oxygen; or
- Renal failure, as defined by chronic dialysis > 6 months or renal transplantation.
- Functional status as determined by the Modified Scleroderma Health Assessment Questionnaire (m-HAQ/S-HAQ) [ Time Frame: 44 months after subject enrollment ] [ Designated as safety issue: No ]
- Mortality due to any cause [ Time Frame: 44 months after subject enrollment ] [ Designated as safety issue: Yes ]
- Medical therapies and procedures (including hospitalizations) [ Time Frame: 44 months after subject enrollment ] [ Designated as safety issue: No ]
- Diagnosis and treatment for pulmonary hypertension [ Time Frame: 44 months after subject enrollment ] [ Designated as safety issue: Yes ]
- Need for hyperalimentation [ Time Frame: 44 months after subject enrollment ] [ Designated as safety issue: Yes ]
- Amputation whether surgical or auto-amputation [ Time Frame: 44 months after subject enrollment ] [ Designated as safety issue: Yes ]
- Hospitalization or surgery [ Time Frame: 44 months after subject enrollment ] [ Designated as safety issue: Yes ]
|Study Start Date:||June 2005|
|Study Completion Date:||March 2016|
|Primary Completion Date:||March 2016 (Final data collection date for primary outcome measure)|
Drug: currently available therapy in the community
For multiple reasons, the SCOT investigators and the sponsor of the SCOT trial, the Division of Allergy, Immunology, and Transplantation (DAIT) of the National Institute of Allergy and Infectious Diseases (NIAID), determined that it is important to track the course of a 'matched' group of patients, who are not exposed to these treatments but receive currently available therapy in the community. First, such a group will provide information to determine if the SCOT entry criteria do indeed identify these high-risk individuals. More importantly, such a group of patients is likely to be treated with a variety of medical regimens, including some immunosuppressive therapy with cyclophosphamide or other immunosuppressive agents that may modify the natural history of the disease. In evaluating the relative efficacy of the two treatment regimens, it will be important to assess whether outcomes in the subjects treated under the SCOT protocol have outcome profiles that differ from those associated with the matched group of patients treated in the community. One readily available group that meets these criteria are those individuals who are otherwise eligible for the SCOT trial but fail to be randomized because they either decline to participate or are denied insurance coverage to receive the SCOT treatment regimens.
The duration of this trial is 44 months. Participants will be enrolled over the same period as the SCOT trial. Participants will follow the course of treatment prescribed by their treating physician with no interference from the registry. All participant contact, including obtainment of informed consent and telephone interview regarding outcome measurements will be performed by SCOT study personnel at the University of Texas, Houston (one of the SCOT transplant centers). Participants will be contacted by phone every 3 months to determine vital status, record medical and other therapy, and administer the modified Scleroderma Health Assessment Questionnaire (S-HAQ). Medical records will be obtained to verify self-reported medical events.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00860548
|United States, Texas|
|University of Texas, Houston Medical School|
|Houston, Texas, United States, 77030|
|Study Chair:||Maureen Mayes, MD, MPH||The University of Texas Health Science Center, Houston|
|Study Chair:||Daniel Furst, MD||UCLA Medical School|
|Study Chair:||Peter McSweeney, MD||Blood and Marrow Transplant Program, Presbyterian/St. Luke's Medical Center, Rocky Mountain Cancer Center|
|Study Chair:||Leslie J. Crofford, MD||University of Michigan|
|Study Chair:||Richard Nash, MD||Fred Hutchinson Cancer Research Center|
|Study Chair:||Keith Sullivan, MD||Division of Cellular Therapy, Duke University|